Tenpoint Therapeutics and Visus Therapeutics have merged to advance innovative treatments for presbyopia and other ocular conditions. Tenpoint, established in July 2023 with a $70 million Series A financing, focuses on engineered cell-based therapies and in vivo reprogramming to restore vision lost due to degenerative eye diseases.
Visus Therapeutics is known for its lead candidate, Brimochol PF, a preservative-free eye drop designed to improve near vision in presbyopia patients.
The merger aims to combine Tenpoint’s regenerative medicine expertise with Visus’s clinical-stage ophthalmic solutions, particularly targeting the development and commercialization of presbyopia-correcting eye drops. This strategic partnership seeks to enhance the efficacy and accessibility of treatments for age-related vision impairments, leveraging both companies’ strengths to address unmet needs in ophthalmology.
By uniting their resources and expertise, Tenpoint and Visus plan to accelerate the clinical development of innovative therapies, with the goal of bringing effective solutions to patients suffering from presbyopia and other degenerative eye conditions.
